Cargando…

Ten-year survival in glioblastoma patient with neurofibromatosis type 1: illustrative case

BACKGROUND: Gliomas are commonly detected in patients with neurofibromatosis type 1 (NF1) at an early age. Few patients with NF1 are diagnosed with glioblastoma. The course of management, response to therapy, and prognosis of such patients are unknown. Few reports have shown longer-than-average surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Basindwah, Sarah, Alkhalidi, Hisham, Abdelwarith, Ahmed, Elwatidy, Sherif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Neurological Surgeons 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379713/
https://www.ncbi.nlm.nih.gov/pubmed/36130570
http://dx.doi.org/10.3171/CASE21630
_version_ 1784768729149603840
author Basindwah, Sarah
Alkhalidi, Hisham
Abdelwarith, Ahmed
Elwatidy, Sherif
author_facet Basindwah, Sarah
Alkhalidi, Hisham
Abdelwarith, Ahmed
Elwatidy, Sherif
author_sort Basindwah, Sarah
collection PubMed
description BACKGROUND: Gliomas are commonly detected in patients with neurofibromatosis type 1 (NF1) at an early age. Few patients with NF1 are diagnosed with glioblastoma. The course of management, response to therapy, and prognosis of such patients are unknown. Few reports have shown longer-than-average survival rates for patients with NF1 with glioblastoma. OBSERVATIONS: A 27-year-old man with NF1 presented with symptoms of high intracranial pressure. Imaging and pathology showed left frontotemporal glioblastoma. Gross total resection was achieved, and concurrent chemoradiotherapy was administered. Recurrence of tumor was detected 48 months later, and the patient underwent tumor debulking and concurrent chemoradiotherapy. The patient received first-, second-, and third-line chemotherapy (temozolomide, bevacizumab, bevacizumab/irinotecan) with good tolerance and has survived >10 years since then with good functional status. LESSONS: This case demonstrates >10 years overall survival of glioblastoma in a patient with NF1. Reports of patients with NF1 with longer survival may be attributed to the young age at diagnosis and relatively better tolerance for therapy. It might also support the growing evidence of a unique subset of glioblastoma associated with NF1 and opens the door for a more molecular targeted therapy in the future.
format Online
Article
Text
id pubmed-9379713
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association of Neurological Surgeons
record_format MEDLINE/PubMed
spelling pubmed-93797132022-10-04 Ten-year survival in glioblastoma patient with neurofibromatosis type 1: illustrative case Basindwah, Sarah Alkhalidi, Hisham Abdelwarith, Ahmed Elwatidy, Sherif J Neurosurg Case Lessons Case Lesson BACKGROUND: Gliomas are commonly detected in patients with neurofibromatosis type 1 (NF1) at an early age. Few patients with NF1 are diagnosed with glioblastoma. The course of management, response to therapy, and prognosis of such patients are unknown. Few reports have shown longer-than-average survival rates for patients with NF1 with glioblastoma. OBSERVATIONS: A 27-year-old man with NF1 presented with symptoms of high intracranial pressure. Imaging and pathology showed left frontotemporal glioblastoma. Gross total resection was achieved, and concurrent chemoradiotherapy was administered. Recurrence of tumor was detected 48 months later, and the patient underwent tumor debulking and concurrent chemoradiotherapy. The patient received first-, second-, and third-line chemotherapy (temozolomide, bevacizumab, bevacizumab/irinotecan) with good tolerance and has survived >10 years since then with good functional status. LESSONS: This case demonstrates >10 years overall survival of glioblastoma in a patient with NF1. Reports of patients with NF1 with longer survival may be attributed to the young age at diagnosis and relatively better tolerance for therapy. It might also support the growing evidence of a unique subset of glioblastoma associated with NF1 and opens the door for a more molecular targeted therapy in the future. American Association of Neurological Surgeons 2022-01-24 /pmc/articles/PMC9379713/ /pubmed/36130570 http://dx.doi.org/10.3171/CASE21630 Text en © 2022 The authors https://creativecommons.org/licenses/by-nc-nd/4.0/CC BY-NC-ND 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Case Lesson
Basindwah, Sarah
Alkhalidi, Hisham
Abdelwarith, Ahmed
Elwatidy, Sherif
Ten-year survival in glioblastoma patient with neurofibromatosis type 1: illustrative case
title Ten-year survival in glioblastoma patient with neurofibromatosis type 1: illustrative case
title_full Ten-year survival in glioblastoma patient with neurofibromatosis type 1: illustrative case
title_fullStr Ten-year survival in glioblastoma patient with neurofibromatosis type 1: illustrative case
title_full_unstemmed Ten-year survival in glioblastoma patient with neurofibromatosis type 1: illustrative case
title_short Ten-year survival in glioblastoma patient with neurofibromatosis type 1: illustrative case
title_sort ten-year survival in glioblastoma patient with neurofibromatosis type 1: illustrative case
topic Case Lesson
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379713/
https://www.ncbi.nlm.nih.gov/pubmed/36130570
http://dx.doi.org/10.3171/CASE21630
work_keys_str_mv AT basindwahsarah tenyearsurvivalinglioblastomapatientwithneurofibromatosistype1illustrativecase
AT alkhalidihisham tenyearsurvivalinglioblastomapatientwithneurofibromatosistype1illustrativecase
AT abdelwarithahmed tenyearsurvivalinglioblastomapatientwithneurofibromatosistype1illustrativecase
AT elwatidysherif tenyearsurvivalinglioblastomapatientwithneurofibromatosistype1illustrativecase